Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo

Cancer Research

Volumn 67, Issue 23, 2007, Pages 11244-11253

  Li, Ji Liang ^a   Sainson, Richard C A ^a   Shi, Wen ^a   Leek, Russell ^a   Harrington, Laura S ^a   Preusser, Matthias ^b   Biswas, Swethajit ^a   Turley, Helen ^a   Heikamp, Emily ^a   Hainfellner, Johannes A ^c   Harris, Adrian L ^a,d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Department of Internal Medicine 1 ^*  (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; MEMBRANE PROTEIN; PROTEIN DLL4; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD VESSEL; CELL FUNCTION; CELL PROLIFERATION; CONTROLLED STUDY; GENE CONTROL; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; UPREGULATION; VASCULAR TUMOR; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CELLS, CULTURED; CHO CELLS; CRICETINAE; CRICETULUS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSPLANTATION, HETEROLOGOUS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 37049012486     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0969     Document Type: Article

References (38)

1. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65:671-80.
2. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.
3. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signalling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
4. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signalling: cell fate control and signal integration in development. Science 1999;284:770-6.
5. Iso T, Kedes L, Hamamori Y. HES and HERP families: multiple effectors of the Notch signalling pathway. J Cell Physiol 2003;194:237-55.
6. Iso T, Maeno T, Oike Y, et al. Dll4-selective Notch signalling induces ephrinB2 gene expression in endothelial cells. Biochem Biophys Res Commun 2006;341:708-14.
7. Hofmann JJ, Luisa Iruela-Arispe M. Notch expression patterns in the retina: an eye on receptor-ligand distribution during angiogenesis. Gene Expr Patterns 2007;7:461-70.
8. Iso T, Hamamori Y, Kedes L. Notch signalling in vascular development. Arterioscler Thromb Vasc Biol 2003;23:543-53.
9. Joutel A, Corpechot C, Ducros A, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-10.
10. Li L, Krantz ID, Deng Y, et al. Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. Nat Genet 1997;16:243-51.
11. Oda T, Elkahloun AG, Pike BL, et al. Mutations in the human Jagged1 gene are responsible for Alagille syndrome. Nat Genet 1997;16:235-42.
12. Duarte A, Hirashima M, Benedito R, et al. Dosage-sensitive requirement for mouse Dll4 in artery development. Genes Dev 2004;18:2474-8.
13. Gale NW, Dominguez MG, Noguera I, et al. Haploin-sufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004;101:15949-54.
14. Krebs LT, Shutter JR, Tanigaki K, Honjo T, Stark KL, Gridley T. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 2004;18:2469-73.
15. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
16. Li JL, Harris AL. Notch signalling from tumor cells: a new mechanism of angiogenesis. Cancer Cell 2005;8:1-3.
17. Rehman AO, Wang CY. Notch signalling in the regulation of tumor angiogenesis. Trends Cell Biol 2006;16:293-300.
18. Zeng Q, Li S, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signalling. Cancer Cell 2005;8:13-23.
19. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001;69:135-44.
20. Patel NS, Dobbie MS, Rochester M, et al. Upregulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006;12:4836-44.
21. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005;65:8690-7.
22. Shutter JR, Scully S, Fan W, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 2000;14:1313-8.
23. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006;107:931-9.
24. Liu ZJ, Shirakawa T, Li Y, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003;23:14-25.
25. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumor growth by promoting non-productive angiogenesis. Nature 2006;444:1032-7.
26. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumor growth by deregulating angiogenesis. Nature 2006;444:1083-7.
27. Scehnet JS, Jiang W, Kumar SR, et al. Inhibition of Dll4-mediated signalling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007;109:4753-60.
28. Chekenya M, Hjelstuen M, Enger PO, et al. NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. Faseb J 2002;16:586-8.
29. Grako KA, Stallcup WB. Participation of the NG2 proteoglycan in rat aortic smooth muscle cell responses to platelet-derived growth factor. Exp Cell Res 1995;221:231-40.
30. Hicks C, Ladi E, Lindsell C, et al. A secreted Delta1-Fc fusion protein functions both as an activator and inhibitor of Notch1 signalling. J Neurosci Res 2002;68:655-67.
31. Hukriede NA, Gu Y, Fleming RJ. A dominant-negative form of Serrate acts as a general antagonist of Notch activation. Development 1997;124:3427-37.
32. Sun X, Artavanis-Tsakonas S. Secreted forms of DELTA and SERRATE define antagonists of Notch signalling in Drosophila. Development 1997;124:3439-48.
33. Naumov GN, Akslen LA, Folkman J. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-87.
34. Lawson ND, Scheer N, Pham VN, et al. Notch signalling is required for arterial-venous differentiation during embryonic vascular development. Development 2001;128:3675-83.
35. Zhong TP, Childs S, Leu JP, Fishman MC. Gridlock signalling pathway fashions the first embryonic artery. Nature 2001;414:216-20.
36. Uyttendaele H, Ho J, Rossant J, Kitajewski J. Vascular patterning defects associated with expression of activated Notch4 in embryonic endothelium. Proc Natl Acad Sci U S A 2001;98:5643-8.
37. Kleihues P, Cavenee W. World Health Organisation classification of tumors: pathology and genetics of tumors of the nervous system. 1st ed. Lyon: IARC Press; 2000.
38. Birner P, Piribauer M, Fischer I, et al. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 2003;13:133-43.